# Tirzepatide Reduces Death Risk in Patients With Heart Failure
Tirzepatide, the active ingredient in the diabetes drug Mounjaro and weight loss medication Zepbound, reduces death risk for people living with heart failure, new research shows.
A study published in the New England Journal of Medicine found that patients taking tirzepatide experienced a 38 percent lower risk of death from any cause compared to those receiving a placebo. The drug also cut the risk of hospitalization for worsening heart failure by 25 percent. Researchers followed more than 3,000 patients with heart failure and obesity over approximately 18 months.
This outcome matters because heart failure remains a leading cause of death globally, and options to reduce mortality rates remain limited. Heart failure occurs when the heart weakens and cannot pump blood efficiently to the body. Excess weight worsens the condition by forcing the heart to work harder.
Tirzepatide belongs to a drug class called GLP-1 receptor agonists, which mimic a hormone that regulates appetite and blood sugar. The medication suppresses hunger, leading to weight loss that directly improves heart function. Participants in the study lost an average of 10 percent of their body weight while taking tirzepatide.
The findings extend tirzepatide's benefits beyond glucose control and weight management. Previous research demonstrated the drug reduces cardiovascular events in people with type 2 diabetes. This new evidence suggests the benefits apply broadly to heart failure patients, regardless of diabetes status.
Cardiologists view these results as potentially practice-changing. The dramatic reduction in mortality offers a new tool for managing a complex condition that affects roughly 6 million Americans. Weight loss through tirzepatide appears to strengthen the heart's pumping ability and reduce inflammation driving heart disease progression.
Access and cost remain barriers for many patients.